Tetrahydrothiopyran-3-carboxaldehyde (CAS 61571-06-0)
Tetrahydrothiopyran-3-carboxaldehyde
CAS 61571-06-0 · C6H10OS · MW 130.21 g/mol
Caricamento molecola...
Letteratura scientifica
Related literature
20 artykułów · 8 open access · Źródła: PubMed, OpenAlex, Semantic Scholar
📈 Timeline publikacji (20 artykułów)
Wysokość słupka = liczba artykułów w roku. Hover dla szczegółów.
A. Lamarca, D. Palmer, H. Wasan et al. (2021) · The Lancet Oncology
AI Summary
The addition of FOLFOX to ASC improved median overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, with a clinically meaningful increase in 6-month and 12-month overall survival rates.
The addition of FOLFOX to ASC improved median overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, with a clinically meaningful increase in 6-month and 12-month overall survival rates.
G. Curigliano, Xichun Hu, R. Dent et al. (2024) · Journal of Clinical Oncology
AI Summary
T-DXd showed a statistically significant and clinically meaningful PFS benefit vs TPC (CT) in HER2-low mBC and establishes T-DXd as a standard of care following ≥1 endocrine-based therapy for pts with HER2-low and -ultralow, HR+ mBC.
T-DXd showed a statistically significant and clinically meaningful PFS benefit vs TPC (CT) in HER2-low mBC and establishes T-DXd as a standard of care following ≥1 endocrine-based therapy for pts with HER2-low and -ultralow, HR+ mBC.
V. Mollica, Alessandro Rizzo, Andrea Marchetti et al. (2023) · Clinical and Experimental Medicine (Testo stampato)
AI Summary
The pooled results showed that immunotherapy, either alone or in combination, reduces the risk of death or progression in both ECOG PS 0 and 1 populations, and the survival benefit was consistent in all subgroups.
The pooled results showed that immunotherapy, either alone or in combination, reduces the risk of death or progression in both ECOG PS 0 and 1 populations, and the survival benefit was consistent in all subgroups.
C. Aubin, T. Blum, M. Golterman et al. (2022) · Physical Review D
S. Loi, A. Giobbe-Hurder, A. Gombos et al. (2018)
M. Lambertini, C. Campbell, R. Gelber et al. (2019) · Breast Cancer Research and Treatment
AI Summary
HER2-positive early breast cancer is characterized by the presence of two diseases with distinct natural history based on HR status requiring the development of different follow-up strategies and future de-escalation and escalation clinical trials.
HER2-positive early breast cancer is characterized by the presence of two diseases with distinct natural history based on HR status requiring the development of different follow-up strategies and future de-escalation and escalation clinical trials.
Rui Liu, Yong-Kai Ma, Lei Chen et al. (2023) · Frontiers in Microbiology
Yifeng Li, Yongqiu Qiu, Xu Zhang et al. (2019) · Bioresources and Bioprocessing
M. Talamonti, M. Galluzzo, A. Zangrilli et al. (2017) · Molecular Diagnosis & Therapy
AI Summary
Adalimumab reduced long-term severity in patients with moderate-severe psoriasis, independent of their HLA-C*06:02 status.
Adalimumab reduced long-term severity in patients with moderate-severe psoriasis, independent of their HLA-C*06:02 status.
Jiachen Jiang, Askar B. Abdikamalov, C. Bambi et al. (2022) · Monthly notices of the Royal Astronomical Society
Kankan Patra, Samraj Mollick, Haridas Pal et al. (2025) · ACS Applied Materials & Interfaces
Mardeen S. Karim, Ben J. Friedman, Sasank Konda (2025) · Journal of the American Academy of Dermatology
· Manchuria Daily News Online
(2015)
Stacey Hanzel, Kim Lenters (2020) · Literacy
$ PaywallDOI ↗
Z Zeng, AH Vo, Y Luo et al. (2019) · Cancer Research
$ PaywallDOI ↗
· Manchuria Daily News Online
$ PaywallDOI ↗
KC Scribner, WW. Porter (2010) · Cancer Research
$ PaywallDOI ↗
M Ferrari, R Xu, G Zhang et al. (2017) · Cancer Research
$ PaywallDOI ↗
Dane z PubMed (NIH NLM), OpenAlex (CC0), Semantic Scholar (AI2). AI Summary wygenerowane przez Semantic Scholar TLDR. Artykuły z ikoną 
wymagają płatnego dostępu.